

1 Distinct and overlapping immunological responses to SARS-CoV-2 and
2 *Mycobacterium tuberculosis* identified by single-cell RNA-seq of co-
3 infected whole blood

4

5 Dylan Sheerin^{1,2,*}, Thanh Kha Phan^{1,3}, Emily M. Eriksson^{2,4}, COVID PROFILE Consortium, Anna K
6 Coussens^{1,2,5}

7 ¹ Infectious Diseases and Immune Defence Division, Walter and Eliza Hall Institute of Medical
8 Research, VIC 3052, Australia

9 ² Department of Medical Biology, The University of Melbourne, VIC 3052, Australia

10 ³ La Trobe Institute for Molecular Science, Department of Biochemistry and Chemistry, School of
11 Agriculture, Biomedicine and Environment, La Trobe University, Melbourne, Australia

12 ⁴ Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research,
13 VIC 3052, Australia

14 ⁵ Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and
15 Molecular Medicine, Department of Pathology, University of Cape Town, South Africa

16 *** Correspondence:**

17 Dylan Sheerin

18 sheerin.d@wehi.edu.au

19

20

21 **Keywords: Tuberculosis, COVID-19, co-infection, single-cell RNA-sequencing, apoptosis.**

22

23 **Abstract**

24 Introduction:

25 COVID-19 and tuberculosis (TB) exhibit similar symptomatic presentation and clinical parameters.
26 Common underlying immunological mechanisms also highlight potential routes of
27 immunopathogenic interaction between these diseases during co-infection. To explore
28 immunological similarities, differences and interactions, single-cell RNA-seq (scRNA-seq) was
29 performed on whole blood infected with *Mycobacterium tuberculosis* (*Mtb*), SARS-CoV-2, or both
30 pathogens.

31 Methods:

32 Whole blood from four healthy adults, were subjected to *ex vivo* infection with *Mtb* and/or SARS-
33 CoV-2 ancestral strain, or were maintained in an uninfected state, for 24 or 96 hours. At each
34 timepoint, for each condition, the four biological replicates were captured, fixed and cryopreserved to
35 be processed for scRNA-seq as a single batch. Following quality control filtering, genotype-based
36 demultiplexing was performed to obtain data from each biological replicate for pseudobulk
37 differential expression analysis.

38 Results:

39 Thirteen distinct clusters of cells were identified based on marker gene expression. Profound
40 differences in the proportions of monocytes, T cells and neutrophils were observed between infection
41 conditions and timepoints. The greatest divergence between pathogen responses occurred within
42 myeloid cells at early timepoints of infection. Co-infection had the greatest synergistic effect 24
43 hours post-infection with 238 immunological pathways uniquely enriched, including IFN- γ and TNF
44 production, whilst by 96 hours post-infection there was a large overlap of 182 shared pathways
45 between *Mtb*, SARS-CoV-2 and co-infection. SARS-CoV-2-only infection resulted in widespread
46 cell death by 96 hours post-infection, while *Mtb*-only and co-infected samples remained enriched for
47 monocyte, T cell and NK cell signatures, sharing negative regulation of extrinsic apoptotic signalling.
48 Distinct from *Mtb*, SARS-CoV-2 had unique regulating of $\alpha\beta$ T cell activation and differentiation at
49 both time points.

50 Conclusion:

51 These data provide a high-resolution characterisation of distinct and overlapping immunological
52 responses generated by SARS-CoV-2 and *Mtb* when a single infection or co-infection occurs. This
53 sheds light on the potential effects of novel or existing host-directed therapies that target these
54 pathways, which is particularly crucial for settings where dual presentation is common.

55

56

57 **Introduction**

58 The COVID-19 pandemic has had a substantial impact on global progress towards tuberculosis
59 (TB) elimination, primarily through disruptions to TB diagnosis and treatment services [1, 2]. There
60 was a precipitous drop in TB notifications in 2020 and, according to numbers derived from the most
61 recent World Health Organization report, annual deaths from TB have increased between 2019 and
62 2021 for the first time since 2005 [3], reversing a trend of slow but sustained decline. Beyond
63 impacting TB health services, the Global Tuberculosis Network conducted a prospective multi-
64 country register-based cohort study involving 175 centres across 37 countries, identifying 767
65 dually diagnosed TB/COVID-19 patients which provided evidence that TB patients suffer worse
66 outcomes when co-infected by COVID-19 [4]. They found that TB/COVID-19 patients experienced
67 11.1% mortality, compared to 1-2% for COVID-19 alone. A large multi-variate analysis of
68 3,460,932 patients in South Africa found that current and previous TB increased COVID-19
69 mortality with adjusted hazard ratios of 2.7 and 1.5, respectively [5]. Despite these epidemiological
70 findings, the immunopathologic interaction between TB and COVID-19 that increases mortality
71 risk remains poorly understood.

72 The effects of co-infection with *Mycobacterium tuberculosis* (*Mtb*) and SARS-CoV-2 on host
73 immune responses have scarcely been explored in the literature to date. Most published studies have
74 focused on the impact of co-infection on antigen-specific responses to *Mtb* and SARS-CoV-2.
75 These studies have reported that active (clinical) TB limits interferon (IFN)- γ responses to SARS-
76 CoV-2 antigen *in vitro* [6], that COVID-19 patients have lower levels of *Mtb*-specific CD4+ T cells
77 [7] and that “latent” TB infection alters humoral responses to SARS-CoV-2 infection [8] and *vice*
78 *versa* [9]. A mouse study of *Mtb*/SARS-CoV-2 co-infection demonstrated alteration of the cytokine
79 profile and loss of granulomatous control of *Mtb* in the lung, leading to *Mtb* dissemination [10].
80 Most recently, immune profiling of TB/COVID-19 co-infected patients revealed significant
81 impairment of antigen-specific responses to the virus and diminished *in vitro* *Mtb*-specific
82 responses in co-infected patients compared with those with TB-only [11]. Taken together, these
83 data demonstrate an alteration of the ability of the host to respond to and control *Mtb* and/or SARS-
84 CoV-2 in the event of co-infection, prompting further exploration of the underlying immunological
85 pathways.

86 We previously performed a patient-level meta-analysis of published COVID-19 immune cell
87 signatures on publicly available TB RNA-seq datasets to identify potential immunological hotspots
88 that could exacerbate disease, identifying neutrophil, monocyte, lung macrophage subpopulations,

89 interferon and complement signalling particularly shared between severe COVID-19 and active and
90 subclinical TB [12]. However, a detailed exploration of the responses to genuine co-infection in
91 humans was lacking. We therefore elected to study these responses in human whole blood at single-
92 cell (sc) resolution by subjecting blood samples from four healthy adults to *ex vivo* infection with
93 *Mtb* and/or SARS-CoV-2 for subsequent scRNA-seq at 24 and 96 hours post-infection (p.i.). By
94 defining longitudinal gene expression changes induced by each infectious agent, relative to
95 uninfected samples, and comparing these responses with co-infected samples, we were able to
96 discern unique aspects of the immune response to each pathogen and which responses are
97 exacerbated by co-infection. The present study provides the most comprehensive overview of the
98 immunological interaction between these two globally significant pathogens to date.

99

100 **Materials and Methods**

101 ***Mycobacterium tuberculosis* Single Cell Stock Generation**

102 T25 flasks (Sigma Aldrich) containing 10 mL 7H9 (Difco™ Middlebrook 7H9 broth, Becton
103 Dickinson)/ADC (Becton Dickinson) media containing 0.05% Tween-80 (Sigma-Aldrich) were
104 inoculated with 500 µL frozen aliquots of the *Mtb* lineage 4 laboratory strain H37Rv. Flasks were
105 incubated at 37°C for 10 days. Cultures were transferred to 50 mL Falcon tubes (Fisher Scientific)
106 using a serological pipette on day 10 during exponential growth phase. One millilitre of culture was
107 transferred to a 500 mL flask containing 100 mL 7H9/ADC media without Tween-80 and incubated
108 at 37°C for a further 10 days, swirling intermittently after day four. On day 10, 50 mL aliquots were
109 centrifuged at 3000 x *g* for 5 minutes at room temperature. Supernatants were removed and ~10
110 glass beads (2–3 mm, Sigma-Aldrich) were added to the pellets and shaken vigorously for 1 minute.
111 Six mL Dulbecco's phosphate-buffered saline (DPBS, ThermoFisher) was added to each tube and
112 mixed by inversion before allowing clumps to decant for 10 minutes. The upper 5 mL was decanted
113 into a separate tube and centrifuged at 260 x *g* for 10 minutes at room temperature. The upper 4.5
114 mL of supernatant was transferred into a new tube containing 0.5 mL 50% glycerol (ThermoFisher)
115 and aliquots stored at -80°C. One frozen aliquot was serially diluted in quadruplicate for plating on
116 three-sector 7H10 (Difco™ Middlebrook 7H10 agar, Becton Dickinson)/ADC plates for colony
117 forming unit (CFU) determination, incubated at 37°C and counted after 10, 14 and 21 days.

118 **SARS-CoV-2 Stock Preparation**

119 Vero (CCL-81, ATCC) cells were cultured in T150 flasks in Dulbecco's Modified Eagle Medium
120 (DMEM + 1 g/L D-glucose, L-glutamine and 110 mg/L sodium pyruvate, ThermoFisher) + 10%
121 heat-inactivated foetal bovine serum (FBS, Sigma-Aldrich) until confluent. Media was removed and
122 adherent cells were washed twice with DPBS before replacing with 10 mL serum-free DMEM. A
123 single 1 mL vial of VIC001 (24/03/21) SARS-CoV-2 stock (1×10^6 tissue culture infectious dose
124 50 [TCID50]/mL, obtained from The Peter Doherty Institute for Infection and Immunity,
125 Melbourne, Australia) was thawed. Infection media was made up by adding VIC001 stock to
126 serum-free DMEM to achieve an MOI of 0.01 (1×10^5 TCID50 for $\sim 1 \times 10^7$ cells) and adding
127 TPCK-treated trypsin (ThermoFisher) to a final concentration of 1 µg/mL. 2.5 mL of infection
128 media was added to the Vero cells in the flask after removing the serum-free media and incubated at
129 37°C with 5% CO₂ for 30 minutes. 20 mL of serum-free DMEM + TPCK trypsin was added to the
130 flask and incubated at 37°C with 5% CO₂ for 48 hours or until sufficient cytopathic effect was
131 observed under the microscope.

132 Infection media was removed from the T125 flask, transferred to a 50 mL Falcon tube and
133 centrifuged at 3000 x g for 10 mins to pellet the debris. Supernatant was transferred to a separate 50
134 mL Falcon tube, taking care to avoid the pellet, and then aliquoted into 1 mL Nunc® CryoTubes®
135 to be stored at -80°C. Vero cells were seeded in flat-bottomed 96-well plates (ThermoFisher) at a
136 density of 1×10^4 cells/well and incubated at 37°C with 5% CO₂ overnight to achieve confluency.
137 Media was removed from wells and cells were washed twice with DPBS before replacing with 125
138 µL of DMEM + TPCCK trypsin [13]. One aliquot was used to measure TCID₅₀ of the stock by
139 diluting in 1:7 serial dilutions five times with six replicates in serum-free DMEM + TPCCK trypsin
140 in a round-bottom 96-well plate (ThermoFisher). Twenty-five microlitres of each dilution was
141 transferred to the appropriate well of the 96-well Vero plate and incubated for four days at 37°C
142 with 5% CO₂. TCID₅₀ values were calculated by scoring wells (positive or negative) for cytopathic
143 effect (CPE) on day four, using the Spearman and Kärber method [14].

144 **Blood Collection**

145 Acquisition of human blood samples and immunological investigations were approved by the
146 Human Research Ethics Committee at the Walter and Eliza Hall Institute (WEHI HREC #18_09LR
147 and #20/08) and Melbourne Health (RMH69108) as part of the COVID PROFILE study [15].
148 Sample and study data were collected and managed using REDCap [16, 17] electronic data capture
149 tools hosted by Clinical Discovery and Translation, WEHI, Parkville, Victoria, Australia. All
150 subjects provided written informed consent to participate in this study, in accordance with the
151 Declaration of Helsinki. Blood collected in sodium heparin tubes from four donors (2 males, 2
152 female) were divided into eight 1 mL aliquots (approximately 5×10^6 cells/mL) for two timepoints
153 (24 and 96 hours) and four conditions – uninfected, *Mtb*-infected, SARS-infected and co-infected.

154 **Blood Infections**

155 *Mtb*-only blood samples were infected with *Mtb* at 4×10^4 CFU in a volume of RPMI equivalent to
156 the volume of blood. For SARS-CoV-2-only, blood samples were pelleted at 300 x g for 5 minutes,
157 plasma were transferred to a clean 15 mL tube (Eppendorf), 5×10^6 viral particles of SARS-CoV-2
158 (MOI 1) was added to a volume of RPMI + TPCCK trypsin equivalent to the volume of supernatant
159 removed and incubated at 37°C for 30 minutes. After incubation, plasma was replaced and RPMI
160 equivalent to the starting volume of blood added. For co-infected samples, RPMI was made up with
161 *Mtb* at 4×10^4 CFU/mL before adding. An equivalent volume of RPMI as also added to uninfected
162 samples. All samples were placed on an orbital rotator in a 37°C incubator with 5% CO₂ for 24 or
163 96 hours.

164 **Single-cell RNA-sequencing**

165 Cells were harvested at the appropriate timepoint by pelleting at 300 x g for 5 minutes, removing
166 supernatant, resuspending pellets in an appropriate volume of red blood cell lysis solution (0.15 M
167 NH₄Cl, 0.01 M KHCO₃, 0.1mM EDTA), incubating for 10 minutes and repeating with an RPMI
168 wash. Cells in a 1 mL RPMI suspension were counted using a Countess automated cell counter
169 (ThermoFisher). Equal numbers of cells from each of the four donors were combined for each
170 condition and a total of eight HIVE™ (Honeycomb Biotechnologies) cell capture devices, one for
171 each condition, were loaded with 30,000 total cells according to manufacturer's instructions to fix
172 cells and sterilise both pathogens. To confirm SARS-CoV-2 inactivation, Honeycomb™ fixative
173 was mixed 1:1 with SARS-CoV-2 RPMI infection media and diluted out to 1:100 final
174 concentration before putting on a Vero cell monolayer. TCID₅₀ assay was performed as detailed
175 above and compared against Vero cells incubated with SARS-CoV-2 RPMI infection media and
176 uninfected Vero cells (Supplementary Figure 1). To confirm *Mtb* inactivation, Honeycomb™
177 fixative was mixed 1:1 with 2 x 10⁴ CFU of *Mtb* in 7H9/ADC growth media, to a total volume of 1
178 mL, and 200 µL was dispensed into triplicate wells of a flat-bottomed 96-well plate
179 (ThermoFisher). Growth media was used as a negative control and growth media + *Mtb* was used as
180 a positive control. The 96-well plate was incubated at 37°C for 14 days before adding alamarBlue
181 (ThermoFisher), at 10% of sample volume to each well, and incubating overnight. Fluorescence
182 was measured at 555-590 nm the next day to determine *Mtb* viability (Supplementary Figure 2).
183 Loaded HIVEs were stored at -80°C until ready for further processing. All eight HIVE™ devices
184 were processed to cDNA in a single batch according to manufacturer's instructions (v1 revision A).
185 Final library concentrations were measured using a KAPA Library Quantification Kit (KAPA
186 Biosystems) and profiled on a TapeStation (Agilent) before pooling at equimolar concentrations for
187 Illumina NextSeq 2000 (Illumina) sequencing with custom primers (Honeycomb Biotechnologies).

188 **Data Analysis**

189 The bespoke HIVE™ BeeNet™ pipeline (v1.1, Honeycomb Biotechnologies,
190 [https://honeycombbio.zendesk.com/hc/en-us/articles/4408694864283-BeeNet-v1-1-X-Software-](https://honeycombbio.zendesk.com/hc/en-us/articles/4408694864283-BeeNet-v1-1-X-Software-Guide)
191 [Guide](https://honeycombbio.zendesk.com/hc/en-us/articles/4408694864283-BeeNet-v1-1-X-Software-Guide)) was used to process the raw data into count matrices. First of all, the *make-ref* function was
192 used to generate a human reference genome index from the GRCh38 Homo sapiens reference
193 genome fasta and annotation gtf files (https://ftp.ensembl.org/pub/release-109/fasta/homo_sapiens/).
194 Fastq files were aligned to this index using the BeeNet™ *align* function and transcript count
195 matrices were obtained for each sample. To demultiplex the four donors combined in each sample,
196 cellsnp-lite [18] was used to pileup expressed alleles in the data and viro [19] was subsequently

197 used to assign cells to donors. Donor ID probabilities obtained from these algorithms were used as
198 metadata for downstream analyses requiring biological replicates.

199 The Seurat pipeline was applied to count matrices for downstream analyses
200 (<https://satijalab.org/seurat/>). A Seurat object was created for each of the eight samples, combined
201 into a merged Seurat list and subjected to quality control filtration. Features with fewer than 500
202 genes and 500 unique transcripts were removed and a threshold of <15% mitochondrial reads was
203 used to filter down to the final total cell numbers per sample for analysis. Each object in the merged
204 list was subjected to log normalization and variable feature identification, using variance stabilising
205 transformation and 2000 features [20]. Objects were integrated by selecting integration features,
206 finding integration anchors based on these features and using the integration anchors as input for the
207 Seurat *IntegrateData* function [21]. The resultant integrated data object was scaled and subjected to
208 principal component (PC) analysis before graph-based K-nearest neighbour cluster identification
209 was performed. Non-linear dimensionality reduction was performed using uniform manifold
210 approximation and projection (UMAP) on the first 10 dimensions.

211 Cell type annotation was conducted using SingleR and the Human Primary Cell Atlas Data obtained
212 via the celldex package [22]. Cluster markers were identified by running the Seurat *FindAllMarkers*
213 function using the default Wilcoxon Rank-Sum test to define differentially expressed genes (DEG).
214 Gene ontology (GO) and Reactome pathway enrichment analysis were performed using the
215 identified markers and by invoking the org.Hs.eg.db, AnnotationDbi and clusterProfiler packages
216 [23]. A stringent *p*-value cut-off of 0.001 was applied after Benjamini Hochberg adjustment for
217 multiple testing.

218 To perform pseudobulk differential expression analysis, the Seurat object was first converted to a
219 SingleCellExperiment class. Cluster counts and metadata for each donor were then aggregated and
220 extracted and used to create DESeq2 [24] objects. Counts were transformed for clustering analyses
221 (Supplementary Figure 3) before running the *DESeq* function. Log₂ fold-change (LFC) shrinkage
222 and Wald tests were performed for each contrast of interest to obtain results tables for all genes.
223 Those with false-discovery rate (FDR)-adjusted *p*-values <0.05 and LFC values >0.58 were deemed
224 significant (Supplementary Table 1–6). GO analyses of pseudobulk data were performed using the
225 clusterProfiler [23] and tmod [25] packages.

226 **Results**

227 **Pathogen-specific changes in immune cell proportions recovered from peripheral blood** 228 **emerge over the course of infection**


229 Following acquisition of scRNA-seq data, quality control analysis was first performed on the raw
230 scRNA-seq data acquired from each individual sample from our 8 biological conditions: uninfected,
231 *Mtb*-only, SARS-CoV-2-only (SARS-only) and co-infection, at 2 time points. Each sample was
232 then filtered to exclude cells with <500 genes/transcripts and >15% of reads mapping to
233 mitochondrial genes (indicative of dying cells). This resulted in total cell counts ranging from 367–
234 3,894 (median 2,340), and an overall total of 18,990 cells. Normalisation and feature selection were
235 performed prior to data integration, and dimensionality reduction was subsequently performed on
236 the integrated data. *ANPEP*, a gene which encodes alanine aminopeptidase, a receptor known to
237 facilitate the binding and entry of coronaviruses, was the top gene contributing to the first principal
238 component (PC1) of the data (Figure 1A). In addition to multiple genes involved in macrophage and
239 endothelial cell adhesion and migration, *RAB31*, which encodes a GTPase implicated in the
240 maturation of phagosomes which engulf *Mtb*, was among the top 10 genes contributing to PC1
241 (Figure 1A).

242 Fourteen clusters were identified based on underlying gene expression differences in the integrated
243 data which were broadly categorised by applying cell type annotation into eight distinct immune
244 cell populations (Figure 1B). The integrated data were then split by infection condition at each time
245 point to begin comparing cell clusters (Figure 1C). Yields for each cell type were similar overall
246 between 24 hours and 96 hours p.i. for the uninfected and *Mtb*-only samples, but there was fewer
247 cells recovered in the SARS-only and co-infected samples at 96 h p.i (Figure 1C, Table 1). SARS-
248 only had the lowest number of cells recovered at this time point, with just 367 remaining after
249 quality filtering (Table 1). Neutrophils made up a greater proportion of the SARS-only and co-
250 infected samples at 24 hours p.i. (68% and 52% of recovered cells, respectively) compared to
251 uninfected and *Mtb*-only (27% and 23%, respectively), with SARS-only having the lowest
252 proportions of CD4+ T cells, CD8+ T cells, B cells and NK cells of all four conditions
253 (Supplementary Figure 4). This represented a 17% and 12% increase for each of the two identified
254 neutrophil populations in the SARS-only samples, relative to the uninfected samples, while the
255 second population accounted for a 33% increase in the co-infected samples (Figure 1D). At 96
256 hours p.i., several immune cell populations were more abundant in the *Mtb*-only samples relative to
257 the uninfected samples (Figure 1D, Table 1), including B cells (88%), LPS-responding neutrophils

258 (95%), NK cells (35%) and CD4+ T cells (33%). With the exception of B cells, the later 3 cell types
259 were also all higher in the co-infected samples compared with the SARS-only samples at this
260 timepoint, suggesting *Mtb* may be sustaining their viability.

Table 1. Cell counts for each of the remaining cells belonging to each annotated immune cell populations after quality control filtration for each infection condition and timepoint.

<i>Cell type</i>	24 hours post-infection				96 hours post-infection			
	Uninfected	<i>Mtb</i> -only	SARS-only	Co-infected	Uninfected	<i>Mtb</i> -only	SARS-only	Co-infected
<i>Monocytes</i>	2158	1106	904	740	2601	1464	190	588
<i>Neutrophils (GM-CSF/IFN-γ)</i>	451	158	979	318	317	92	38	60
<i>Neutrophils (LPS)</i>	618	297	1313	820	93	181	17	56
<i>CD8+ T cells</i>	304	145	70	87	339	275	47	81
<i>CD4+ T cells</i>	247	176	47	138	259	344	46	143
<i>NK cells</i>	67	63	17	55	55	74	15	42
<i>HSC (G-CSF)</i>	34	24	48	28	29	34	9	14
<i>B cells</i>	15	12	2	15	8	15	5	3
<i>Total (18,990)</i>	3894	1981	3380	2201	3701	2479	367	957




263
 264 **Figure 1. Global changes to the transcriptome of human whole blood in response to single or**
 265 **dual *Mtb*/SARS-CoV-2 infection.** **A.** The top 30 genes contributing to the first two principal
 266 components (PC) identified by performing dimensionality reduction on the integrated scRNA-seq
 267 from all eight samples. **B.** Uniform manifold approximation and projection (UMAP) plot depicting
 268 clustering of cells across all eight samples identified by shared nearest neighbour modularity
 269 optimisation. Clusters are here grouped according to either the 14 identified clusters (0-13, left) or
 270 one of eight distinct immune cell type annotations (right). **C.** UMAP plots depicting clustering of
 271 cells across these eight samples separated for each condition (x-axis) and timepoint (y-axis) and

272 coloured by the eight distinct immune cell type annotations. **D.** Bar plots depicting the percentage
273 change in cell count for each of the annotated cell clusters relative to the uninfected samples at the
274 same timepoint, for each infection condition.

275

276 **Distinct immunological pathway enrichment highlights cells responding to infection**

277 For the 14 identified clusters, covering the eight distinct immune cell populations, GO and
278 Reactome biological process (BP) pathway enrichment analyses were performed to determine
279 whether they were associated with distinct immune functions. Pathways were filtered to display the
280 most salient terms in Figure 2, with the full lists provided in Supplementary Tables 7–8. Clusters 1,
281 2, 5 and 7 were associated with the greatest number of significantly enriched pathways. While
282 clusters 2 and 5 are both predicted to be neutrophil populations, cluster 2 is characterised by its
283 response to GM-CSF and IFN- γ , whereas cluster 5 is characterised by its greater enrichment of
284 response to LPS. Cluster 5 was found predominantly in the SARS-only and co-infected samples at
285 24 hours p.i. (Figure 1C); clusters 3 and 6 were also classified as LPS-responding neutrophils but
286 were not associated with statistically significant enrichment of these pathways at this timepoint. The
287 GM-CSF/IFN- γ -responding neutrophils were associated with the largest number of significantly
288 enriched GO pathways and, as predicted by their annotation, they were defined by response to IFN-
289 γ , production of TNF, cytokine signalling, endocytosis and neutrophil migration (Figure 2A).
290 Furthermore, this cluster was significantly enriched for Reactome pathways denoting IFN- α/β
291 signalling, Fc- γ receptor-dependent phagocytosis and interleukin signalling (Figure 2B). The genes
292 implicated in the enrichment of the interleukin signalling term included pro-inflammatory mediators
293 and chemokines *SOD2*, *IRAK1*, *PTAFR*, *IL1B*, *SYK*, *TNFRSF1B*, *CXCL2*, *CSF3R*, *HCK*, *CCL3L1*,
294 *GRB2*, *CCL20*, *CDKN1A*, *CXCL1*, *STAT1*, *CCR1*, *MAP3K8*, *IL1R1*, *CXCL10*, *VEGFA*, *IL1A* and
295 *PTPN12*. Conversely, the LPS-responding neutrophils were exclusively significantly enriched for
296 GO pathways indicating metal ion sequestration and homeostasis (*LCN2*, *FTL*, *TFR2*, *LTF*, *PRNP*,
297 *SLC39A7*, *SLC11A1*, *S100A8* and *S100A9*), regulation of leukocyte cell-cell adhesion, response to
298 chemokine (also confirmed by Reactome pathway analysis, Figure 2B), and negative regulation of
299 cell adhesion and IFN- γ production (Figure 2A). Clusters 1, 7 and 10 represent subsets of
300 monocytes, with clusters 1 and 7 both enriched for antigen processing and presentation via MHC
301 class II. Cluster 7 is exclusively enriched for peptide antigen assembly with MHC class II protein
302 complex, whilst Cluster 1 is exclusively enriched for myeloid leukocyte migration, superoxide
303 anion generation and membrane lipid catabolic process and Cluster 10 is exclusively enriched for
304 foam cell differentiation (*ITGAV*, *PPARG*, *MSR1*, *NR1H3*, *IL18*, *ITGB3* and *LPL*).



305

306 **Figure 2. Substantial immune pathway enrichment underpins identified cell clusters and**
 307 **exhibits greatest divergence between conditions at 24 hours post-infection.** 14 identified
 308 clusters of cells were consolidated to eight immune cell populations based on cluster annotation.
 309 Cell marker genes were identified by performing a Wilcoxon Rank Sum tests between each of the
 310 eight annotated immune cell populations, irrespective of sample. These differentially expressed
 311 gene (DEG) lists were then subjected to a biological process (BP) enrichment analysis using **A.**
 312 gene ontology (GO) or **B.** Reactome pathway annotation. False discovery rate-adjusted p -values are
 313 representing by the shading of data points, while the size corresponds to the number of significant
 314 genes implicated in that pathway. A pseudobulk analysis was performed between infection
 315 conditions at each timepoint by combining cells in each condition and using standard differential
 316 expression (DE) methods, with each of the four composite donor IDs as replicates. Significant
 317 DEGs were then subjected to a BP GO enrichment analysis and the overlap in GO terms was
 318 assessed by venn diagram at **C.** 24 hours and **D.** 96 hours post-infection.

319

320 **Co-infection demonstrates synergistic global immune pathway enrichment at 24 hours, and**
 321 **greater shared pathways by 96 hours, of infection**

322 To ascertain whether differences in immunological pathway enrichment existed between each
323 infection condition, compared to uninfected, a pseudobulk analysis was performed using donor IDs
324 as biological replicates and performing differential expression analyses across all cell types between
325 conditions. A similar GO and Reactome pathway enrichment analysis (Figure 2A-B, Supplementary
326 Table 9-10) was then performed on the significant genes identified (Supplementary Table 1–6).
327 Assessing the unique and overlapping significantly enriched terms revealed distinct aspects of the
328 immune response invoked by each infection condition, at both time points. At 24 hour p.i SARS-
329 only and coinfection shared the greatest overlap in terms (222), compared to only 39 commonly
330 enriched terms between *Mtb*-only and co-infection however, this pattern was switched at 96 hours
331 p.i. with *Mtb*-only and co-infection sharing 114 terms compared to only 62 shared terms between
332 SARS-only and co-infection. This demonstrates that the influence of each pathogen on the
333 transcriptome changes during the course of co-infection, with the influence of *Mtb* increasing
334 during co-infection as it replicates over time.

335 Looking at terms unique to each pathogen, 105 were enriched for *Mtb*-only and 89 for SARS-only
336 at 24 hours p.i.. Of the biologically relevant GO terms for this analysis, certain generic immune cell
337 activation pathways and immune effector processes were uniquely enriched in *Mtb*-only infected
338 cells at 24 hours p.i., while B cell activation (GO:0042113), Fc receptor and STAT signalling
339 (GO:0038094, GO:0097696), and several other cell signalling/response to cytokine GO terms were
340 unique to SARS-only infection (Supplementary Table 9). Amongst the 222 enriched terms shared
341 between SARS-only and co-infection at 24 hours p.i. were $\alpha\beta$ T cell activation and differentiation
342 (GO:0046631, GO:0046632), antimicrobial humoral immune response mediated by antimicrobial
343 peptide (GO:0061844), negative regulation of extrinsic apoptotic signalling (GO:2001237),
344 extracellular matrix disassembly (GO:0022617), negative regulation of cell-cell adhesion
345 (GO:0022408), positive regulation of phagocytosis (GO:0050766), regulation of coagulation
346 (GO:0050818), IFN- γ signalling (GO:0034341), IL-1/2/6 production (GO:0032612, GO:0032623,
347 GO:0032635), leukocyte/lymphocyte proliferation (GO:0070661, GO:0046651) and migration
348 (GO:0050900, GO:0072676), antigen processing and presentation (GO:0019882) and defence
349 response to virus (GO:0051607). Amongst, the 39 terms shared between *Mtb*-only and co-infection
350 at 24 hours p.i. included seven related to cell cycle/division, and others relating to endothelial cell
351 migration (GO:0043542) and regulation of cell differentiation (GO:0045595, Supplementary Table
352 9).

353 By 96 hour p.i. *Mtb*-only and co-infection were enriched for 114 shared terms including negative
354 regulation of extrinsic apoptotic signalling (GO:2001240) and TNF production (GO:0010804),

355 antigen processing and presentation via MHC class II (GO:0002495), cell death in response to
356 oxidative stress (GO:0036473), iron homeostasis (GO:0006879), endothelial cell migration and
357 proliferation (GO:0043542, GO:0001935), LPS metabolic process (GO:0008653), and reactive
358 nitrogen species (GO:2001057); while SARS-only and co-infection shared 62 terms including
359 myeloid cell differentiation (GO:0030099), pattern recognition receptor/TLR signalling
360 (GO:0002221, GO:0002224) and positive regulation of reactive oxygen species metabolic process
361 (GO:2000379). At 96 hours p.i *Mtb* infection had only 16 unique terms (of its total 389), including
362 WNT signalling (GO:0016055), whereas SARS-only infection had the largest number of enriched
363 terms and the largest number of unique terms at this time (513 of 834 terms, ~62%, Figure 2D).
364 However, the unique terms included many variations on terms collectively shared between all three
365 infection conditions at this timepoint (described below) with the additional enrichment of $\alpha\beta$ T cell
366 activation and differentiation (GO:0046631, GO:0046632), ephrin receptor signalling pathway
367 (GO:0048013), Fc epsilon receptor signalling (GO:0038095), granulocyte migration (GO:0097530),
368 intrinsic apoptotic signalling (GO:0097193), macrophage activation (GO:0042116), IL-2/6/8
369 production (GO:0032623, GO:0032635, GO:0032637), monocyte chemotaxis (GO:0002548), and
370 response to IL-1 (GO:0071347) and type I IFN (GO:0034340); many of these terms being shared
371 between SARS-only and co-infection at 24 hours p.i. Thus, over the time course of infection very
372 few of these pathways were unique to SARS-CoV-2 with the majority regulated at one time by both
373 pathogens, just the kinetics varying. Finding the largest enrichment of pathways in the SARS-only
374 infected cells at 96 hours p.i. with this also being the condition with smallest cell recovery, suggests
375 the dominance of the immune response to SARS infection in the absence of *Mtb* co-infection, with
376 the increased cell recovery for co-infected samples perhaps due to survival signals induced by *Mtb*
377 infection.

378 Next, when comparing how the pathogens interact during co-infection, first comparing the
379 similarity between all three conditions (i.e. terms shared with no synergistic effect of co-infection)
380 there were only 18 collectively shared terms at 24 hour p.i (Figure 2C), all of which were related to
381 generic biological functions and not specific to infection (Supplementary Table 9). By contrast, co-
382 infection was associated with 238 uniquely enriched terms the largest number across all infection
383 conditions at 24 hours p.i., indicating the synergistic nature of the response to dual infection,
384 identifying terms not induced by either pathogen alone (Figure 2C); uniquely enriched terms
385 included IFN- γ and TNF production (GO:0034341, GO:0034612), lymphocyte
386 activation/differentiation (GO:0046649, GO:0030098), NK cell-mediated immunity (GO:0002228),
387 T cell signalling (GO:0050852) and positive regulation of viral process (GO:0048525). However by
388 96 hours p.i. only 6 terms were unique to the co-infection group, indicating limited synergistic

389 pathway enrichment, but there were now 182 terms common between *Mtb*-only, SARS-only and
390 co-infection (Figure 2D); these included antimicrobial humoral response, B cell activation, T cell
391 differentiation, reactive oxygen species processes, regulation of viral life cycle, lipoprotein
392 metabolic process, tissue remodeling and receptor mediated endocytosis (Supplementary Table 10).
393 Together this shows that *Mtb* and SARS-CoV-2 share a large overlap in immune pathway
394 enrichment which they each induce during infection with early synergism during co-infection.

395 Finally, at 24 hours p.i there were an additional 10 terms commonly enriched in *Mtb*-only and
396 SARS-only, not shared by co-infection, increasing to 77 commonly enriched terms for the two
397 mono-infections at 96 hours p.i. These terms would be independently but not synergistically
398 regulated by each pathogen, and may include pathways where each pathogen has opposing effects
399 such that during co-infection pathway enrichment is lost.


400

401 **Specific differences between infection conditions are most apparent in innate populations and** 402 **within the first 24 hours of infection**

403 To further examine specific differences and overlapping gene expression between the infection
404 conditions a second pseudobulk analysis was performed, this time at the level of annotated immune
405 cells. For each of the infection conditions, immune cell populations were contrasted against the
406 equivalent cell type in the uninfected group for that timepoint. No significant DEGs were detected
407 in the B cell or haemopoietic stem cell (G-CSF) populations, likely due to the small numbers of
408 cells of this type per donor/condition. The LPS-responding neutrophils at 24 hours p.i. were
409 associated with the greatest number of DEGs across all groups (1,470), with the majority of these
410 induced by co-infection and SARS-only (1,260 total, 434 unique, Supplementary Figure 5),
411 followed next by monocytes (772 total DEG) and neutrophils (GMCSF) (626 total DEG) at 24
412 hours p.i. For all cell types with associated differential expression, there were very few DEGs
413 uniquely associated with *Mtb*-only at 24 hours p.i., at which timepoint SARS-only and co-infection
414 induced the greatest DE, while *Mtb*-only and co-infection induced the greatest DE at 96 hours p.i.
415 when SARS-only induced the least DE of all three conditions (Supplementary Figure 5). This
416 supports a more acute unique transcriptional perturbation associated with SARS-CoV-2 at the initial
417 stages of infection, while *Mtb* induces a response shared by SARS-CoV-2 and co-infection early on
418 which becomes more distinct from SARS-CoV-2 at the later time point after infection is
419 established. The co-infected samples remained highly transcriptionally active throughout both
420 timepoints due to the presence and synergism of both pathogens.

421 Clustering by DEGs identified for monocyte and neutrophil populations generated the cleanest
422 sample clustering by infection condition and timepoint (Figure 3A compared with NK, CD4+ and
423 CD8+ T cell populations (Supplementary Figure 6). At 24hr p.i monocyte expression clustered
424 together for *Mtb*-only and co-infection, whilst co-infection had the most unique monocyte
425 expression at 96 hours p.i., with *Mtb*-only and SARS-only clustering more closely together at this
426 later timepoint. Conversely, patterns of neutrophil gene expression clustering were most distinct at
427 24 hours p.i at which time GM-CSF neutrophils shared a similar expression pattern between *Mtb*-
428 only and SARS-only infections, whilst LPS neutrophils clustered together for co-infection and
429 SARS-only.

430 Finally, the functional enrichment underlying these similarities and differences was assessed at each
431 timepoint. At 24 hours p.i., the majority of enriched pathways were shared by SARS-only and co-
432 infected samples and related to type I IFN responses from monocytes, neutrophils and CD4+ and
433 CD8+ T cells, cell activation (IL-15, IL-23, TNF) of monocytes and neutrophils (GM-CSF, RIG-I
434 like receptor signalling of monocytes, neutrophils (GM-CSF) and CD4+ T cells and viral sensing &
435 immunity; IRF2 targets networks for monocytes and both neutrophil subsets (Figure 3B,
436 Supplementary Table 11). By comparison, there less cell-specific pathway enrichment at 96 hours
437 p.i., with more enrichment at this timepoint shared between *Mtb*-only and co-infection, or all three
438 infection conditions, with monocytes showing the greatest pathway enrichment, particularly for
439 antigen presentation (II & III) and MHC-TLR7-TLR8 cluster, lysosomes in monocytes and both
440 neutrophils and protein synthesis across all cell types, except neutrophils (GM-CSF) (Figure 3C,
441 Supplementary Table 12).



442

443

444

445

446

447

448

449

450

451 module analysis to identify significantly enriched pathways associated with immune cells at **B.** 24
452 hours post-infection and **C.** 96 hours post-infection. False discovery rate-adjusted *p*-values are
453 representing by the shading of data points, while the size corresponds to the number of significant
454 genes implicated in that module.

455 Discussion

456 In the present study, we expand upon our previous work which identified overlapping transcriptional
457 networks of circulating immune cells isolated from TB and COVID-19 patients [12] by delineating
458 host immune cell gene expression programs in response to direct whole blood infection with *Mtb* and
459 SARS-CoV-2 infection. Importantly, we directly compare responses induced by each pathogen alone
460 to what occurs in the context of direct co-infection with both pathogens bringing us closer to an
461 understanding of what is happening at a cellular level during TB/COVID-19 dual presentation. We
462 define the host response pathways underlying differences between immune cell populations reacting
463 to each infection condition across timepoints that appropriately capture innate and adaptive immune
464 cell activity.

465 Despite the extensive use of bulk RNA-seq to study TB disease mechanisms in the blood of patients,
466 there is but one study that defines host responses to *Mtb* by scRNA-seq in this compartment in which
467 they sequenced PBMCs, excluding granulocytes [26]. There is substantial evidence that neutrophil
468 gene expression is an important marker of TB progression [27-29], so any comprehensive
469 characterisation of TB responses in human blood must include them. Despite their absence from a
470 large number of blood scRNA-seq datasets, the COVID-19 scRNA-seq studies that did sequence
471 neutrophils as part of whole blood found them to be an important cell type for distinguishing patients
472 on the basis of disease severity [30, 31]. In our study, two neutrophil clusters emerged based on gene
473 expression markers, neutrophils characterised by their response to GM-CSF/IFN- γ and those with
474 enhanced response to LPS. The later were recovered in greater abundance in SARS-only and co-
475 infected blood at 24 hours p.i, whilst only the GM-CSF neutrophils were enriched uniquely in SARS-
476 only infection. Based on GO enrichment analyses, GM-CSF neutrophils appeared to have greater
477 enrichment of IFN- γ and TNF regulation. These are both key cytokines implicated in *Mtb* control
478 [32-34], so the fact they are not enriched to the same levels during co-infection, although they were
479 more abundant than in *Mtb*-infection alone, suggests *Mtb* is interfering with their regulation by
480 SARS-CoV-2. We previously identified IFN- γ and TNF signalling in the top 20 shared
481 transcriptional pathways in blood of COVID-19 and TB patients and demonstrated *in vitro* that
482 SARS-CoV-2 infected macrophages increase *TNF* and *IFNG* expression when pre-incubated in the
483 inflammatory milieu of *Mtb* infected macrophages, correlating with increased SARS-CoV-2
484 transcript levels [12]. IFN- γ and TNF have been shown to act synergistically in a mouse model of
485 COVID-19 by increasing inflammatory cell death through a process termed 'PANoptosis' [35]. Cell

486 death was also exclusively significantly enriched in these neutrophils in the SARS-only samples at 24
487 hours p.i.. Given the dramatic cell death observed at 96 hours p.i. in SARS-only and co-infected
488 samples, with greater loss of cell recovery in SARS-only compared with co-infected, it is possible
489 that early production of these cytokines from neutrophils may be one of the mechanisms
490 underpinning this. A number of apoptosis regulation GO terms were significantly enriched in SARS-
491 infected samples, with or without *Mtb* co-infection, at 24 hours p.i, including apoptotic cell
492 clearance, extrinsic and intrinsic apoptotic signalling pathways, leukocyte and lymphocyte apoptotic
493 processes and terms associated in the regulation of these pathways (Supplementary Table 9). At 96
494 hours p.i *Mtb*-only and co-infection shared enrichment of negative regulation of extrinsic apoptosis,
495 which may underpin the increased recovered of cells from co-infected compared to SARS-only
496 infected blood at 96 hours p.i. Caspase 8, the mediator of extrinsic apoptosis, has been identified as a
497 critical factor in triggering inflammatory processes the lead to immunopathology in the lungs of
498 COVID-19 patients [36]. Furthermore, caspase 8-dependent T cell apoptosis has been associated with
499 T cell lymphopenia in severe COVID-19 patients, but this process could be prevented *ex vivo* with
500 the use of pan-caspase inhibitors [37]. Given the critical role of T cells in *Mtb* control, early
501 intervention to prevent T cell death from occurring in co-infected patients may be required to prevent
502 TB disease progression.

503 Three neutrophil and monocyte cluster signatures were the greatest determinant of differences
504 between the three infection conditions based on hierarchical clustering analyses. This ties in with
505 evidence that innate immune cell gene expression, rather than lymphoid cells, marks the greatest
506 divergence between COVID-19 severity across patients [30]. Monocytes were the cell type
507 associated with the largest number of significantly enriched pathways, the majority of which were
508 common to SARS-only and co-infected samples, specifically those related to immune activation, type
509 I IFN responses and antigen presentation. Monocytes expressing high levels of HLA-DR and type I
510 IFNs were identified in mild COVID-19 patients in the scRNA-seq study exploring myeloid cell
511 dysregulation [30]. It has been shown that the activation status of monocytes are a correlate of
512 COVID-19 prognosis, with inflammatory phenotypes associated with poorer outcomes [38]. Given
513 that certain circulating monocytes have been identified in TB patients which correlate with disease
514 progression, the induction of these activated, proinflammatory monocytes during co-infection may
515 increase the likelihood of TB disease being advanced in co-infected individuals [39]. By 96 hours p.i.
516 the greatest number of significantly enriched pathways was associated with and common to

517 monocytes from *Mtb*-only and co-infected samples and these pathways were mostly related to
518 lysosome and antigen presentation.

519 The most striking functional response induced by SARS-only/co-infection was the production of
520 IFNs, particularly those classified as type I (α and β). This observation runs counter to some early
521 human studies in which only low levels of type I IFN were measured in COVID-19 patients,
522 irrespective of disease severity [40], and subsequent studies that suggested little in the way of IFN
523 gene expression in peripheral blood from COVID-19 patients but an early transient wave of IFN-
524 stimulated genes (ISGs) [30, 41]. Mouse studies have indicated that the type I IFN response to
525 SARS-CoV-2 contributes more to immunopathology than viral control [42]. In TB, early expression
526 of ISGs in TB contacts has been linked to disease progression and worsened prognosis [29, 43-45].
527 Progression from earlier disease states to clinical TB is typically preceded by a wave of ISG
528 expression [29]. However, there is also evidence that type I IFN responses can be protective in TB
529 [46], and therefore it is likely that the influence of these IFNs on immune cell composition and
530 pathogenesis has a time-dependent effect over the course of TB disease [47]. It is plausible that
531 modulation of the type I IFN response in TB patients with a viral co-infection may alter the balance
532 in such a way as to promote TB disease progression. Over- or under-activation of type I IFN
533 responses is also known to contribute to host pathogenesis for viral infections [48], so it is equally
534 likely that an existing *Mtb* infection could negatively impact control of SARS-CoV-2 and promote
535 more severe disease manifestations. Our previous patient-level meta-analysis of COVID-19
536 signatures on TB datasets indicated that IFN gene signatures associated with COVID-19 severity
537 were highly significantly enriched in whole blood of TB progressors and their expression was the
538 strongest correlate of SARS-CoV-2 replication in macrophages [12], suggesting that the existence of
539 a strong TB IFN signature when SARS-CoV-2 co-infection occurs could be a key determinant of
540 poor outcomes for TB patients.

541 SARS-only samples had much lower proportions of CD4+ T cell, CD8+ T cell, B cell and NK cell
542 recovery at 24 hours. Longitudinal profiling of lymphocyte subsets in COVID-19 patients showed
543 that this occurs in patients shortly after symptom onset, when severe patients have lower proportions
544 of these cell types than those with mild infections, and they reach a nadir at 4–6 days post symptom
545 onset [49]. It has been reported that TB/COVID-19 co-infected patients have lower absolute
546 lymphocyte counts compared with COVID-19 patients [6]. This did not appear to be the case in our
547 study, although co-infected samples had lower proportions of lymphocytes than *Mtb*-only and

548 uninfected samples at 24 hours. We also observed a strong IFN signature in CD4+ and CD8+ T cells
549 at 24 hours p.i. in the SARS-only and co-infected samples. A scRNA-seq study of peripheral blood
550 responses in severe COVID-19 patients noted that the most commonly upregulated genes in these
551 patients were ISGs based on their DE comparison with healthy controls [50]. At 96 hours p.i protein
552 synthesis was commonly significantly enriched across all three infection conditions in CD4+ and
553 CD8+ T cells. Enrichment of this pathway appeared to be mostly driven by expression of cathepsin
554 genes, including *CTSB* and *CTSD*. These genes encode proteases, mainly found in lysosomes, which
555 have been implicated in *Mtb* survival[51] and mediating SARS-CoV-2 binding [52].

556 The SARS-only samples had a greater proportion of B cells at 96 hours p.i.; several studies have
557 noted an increase in the frequency of plasmablasts in severe COVID-19 patients [41, 53, 54].
558 However, this cell type was not captured at sufficient levels to perform any meaningful comparisons
559 between groups to ascertain its function. NK cell proportions remained consistent in *Mtb*-only
560 samples, as has been observed in TB patients compared even with TB-HIV co-infected patients [55,
561 56]. Only samples that were *Mtb*-infected had any significant pathway enrichment in NK cells, with
562 enrichment for protein synthesis, including expression of *CTSD* as well as *PSAP* and *TPT1*, at the 96-
563 hour timepoint. There is evidence that NK cell functionality plays a protective role by combating *Mtb*
564 during HIV infection [57] that may also apply to other co-infections.

565 Our study is limited by the fact that we are studying the responses to pathogens in an artificial *ex vivo*
566 infection model, so we do not recapitulate the natural course of infection, including the recruitment of
567 new immune cells to replenish dying ones. Little is known about the mechanisms underlying human
568 immune responses to the initial stages of *Mtb* infection as it is difficult to ascertain when exactly this
569 occurs, while symptoms and diagnostics allow this to be better determined for SARS-CoV-2
570 infection. Our use of a reagent, TPCK trypsin, to cleave the SARS-CoV-2 spike glycoprotein and
571 allow entry into host cells that do not express or have low levels of ACE2 receptor during initial
572 infection also means that this model is not entirely representative of what occurs *in vivo*. This was
573 done to increase the number of infected cells in our model, over the sort experimental timecourse.
574 Human neutrophils have high levels of ACE2 expression and would be naturally infected and
575 macrophages have been shown to be infected with SARS-CoV-2 in human lung autopsy sections and
576 to be a site for viral replication [58]. We have also shown human macrophages to have increased
577 susceptibility to SARS-CoV-2 infection in the absence of TPCK trypsin addition when incubated in
578 *Mtb* inflammatory milieu [12]. Together this suggests there is the potential for ongoing SARS-CoV-2

579 infection of immune cells in our model, following TPCK trypsin removal. As not all cells will be
580 infected, this approach allowed us to induce a reliable bystander response in cells that do not take up
581 the virus that could then be compared between conditions. Despite the fact that SARS-CoV-2
582 transcripts undergo polyadenylation [59], we were unable to detect any viral transcripts in our count
583 matrices. This may be due to insufficient sequencing depth or the capture efficiency of the scRNA-
584 seq method used. Finally, simultaneous infection with *Mtb* and SARS-CoV-2 is unlikely to occur in
585 most cases. With an established *Mtb* infection prior to SARS-CoV-2 infection more likely to reflect
586 the vast majority of cases, as was observed in the TB/COVID Global Study Group report [4].
587 Nevertheless, in any co-infected individual there will always be new cells coming into an infection
588 site, so that over time, irrespective of the first infecting pathogen, once both are present then any
589 subsequent sequence of infection can occur.

590 In summary, we provide the first characterisation of human circulating immune cell gene expression
591 changes resulting from direct *Mtb* and SARS-CoV-2 co-infection. We hope these data will provide a
592 valuable resource for researchers and clinicians to gain insights to better characterise and identify
593 points of potential therapeutic intervention or immunological exacerbation in TB/COVID-19 co-
594 infected patients.

595

596 **Conflict of Interest**

597 *The authors declare that the research was conducted in the absence of any commercial or financial*
598 *relationships that could be construed as a potential conflict of interest.*

599 **Author Contributions**

600 D.S. and A.K.C. conceived and designed the study. E.E. directed the COVID PROFILE clinical
601 study, arranged blood sample collection, SARS-CoV-2 serotyping, and critically reviewed the
602 manuscript. A.K.C. and E.E funded the study. T.K.P. generated SARS-CoV-2 virus stocks and
603 critically reviewed the manuscript. D.S. generated *Mtb* stocks. D.S. performed blood infection
604 experiments and processed samples for scRNA-seq. D.S. performed the data analysis. D.S. prepared
605 the manuscript with editorial input and revisions from A.K.C. All authors approved the manuscript
606 submission.

607 **Funding**

608 The COVID Profile study was supported by WHO Unity funds and WEHI Philanthropic funds. The
609 funders had no role in study design, data collection and analysis. D.S. is supported by WEHI and
610 NHMRC (2020750). A.K.C. is funded by WEHI, philanthropic donors, NHMRC (2020750) and the
611 Australian Respiratory Council.

612 **Acknowledgments**

613 The authors thank Honeycomb Biotechnologies Inc. for allowing us to participate in their early
614 access program, Maureen Forde for collecting blood samples from participants, Coussens Lab
615 members for feedback, the WEHI PC3 Facility manager Kathryn Davidson for facility support, the
616 WEHI Genomics R&D team, especially Rory Bowden, Daniela Zalcenstein, Daniel Brown and Ling
617 Ling, for their input regarding experimental design and analysis, the Pellegrini Lab at WEHI for
618 providing Vero cells and input into SARS-CoV-2 assays, and Stephen Wilcox of the WEHI
619 Genomics Facility for performing Illumina sequencing of samples.

620 **References**

- 621 1. McQuaid, C.F., et al., *The impact of COVID-19 on TB: a review of the data*. Int J Tuberc
622 Lung Dis, 2021. **25**(6): p. 436-446.
- 623 2. Migliori, G.B., et al., *Gauging the impact of the COVID-19 pandemic on tuberculosis*
624 *services: a global study*. European Respiratory Journal, 2021. **58**(5): p. 2101786.
- 625 3. World Health Organization, *Global tuberculosis report 2022*. 2022.
- 626 4. The TB/COVID-19 Global Study Group, *Tuberculosis and COVID-19 co-infection:*
627 *description of the global cohort*. European Respiratory Journal, 2022. **59**(3): p. 2102538.
- 628 5. Western Cape Department of Health in collaboration with the National Institute for
629 Communicable Diseases South Africa, *Risk Factors for Coronavirus Disease 2019 (COVID-*
630 *19) Death in a Population Cohort Study from the Western Cape Province, South Africa*. Clin
631 Infect Dis, 2021. **73**(7): p. e2005-e2015.
- 632 6. Petrone, L., et al., *Coinfection of tuberculosis and COVID-19 limits the ability to in vitro*
633 *respond to SARS-CoV-2*. Int J Infect Dis, 2021. **113 Suppl 1**: p. S82-s87.
- 634 7. Riou, C., et al., *Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity*
635 *and impact of HIV-1 and tuberculosis coinfection*. The Journal of Clinical Investigation,
636 2021. **131**(12).
- 637 8. Rajamanickam, A., et al., *Latent tuberculosis co-infection is associated with heightened levels*
638 *of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection*.
639 Journal of Infection, 2021. **83**(3): p. 339-346.
- 640 9. Rajamanickam, A., et al., *Effect of SARS-CoV-2 seropositivity on antigen – specific cytokine*
641 *and chemokine responses in latent tuberculosis*. Cytokine, 2022. **150**: p. 155785.

- 642 10. Hildebrand, R.E., et al., *Superinfection with SARS-CoV-2 Has Deleterious Effects on*
643 *Mycobacterium bovis BCG Immunity and Promotes Dissemination of Mycobacterium*
644 *tuberculosis*. *Microbiology Spectrum*, 2022. **10**(5): p. e03075-22.
- 645 11. Najafi-Fard, S., et al., *Characterization of the immune impairment of tuberculosis and*
646 *COVID-19 coinfecting patients*. *International Journal of Infectious Diseases*, 2023.
- 647 12. Sheerin, D., et al., *Immunopathogenic overlap between COVID-19 and tuberculosis identified*
648 *from transcriptomic meta-analysis and human macrophage infection*. *iScience*, 2022. **25**(6):
649 p. 104464.
- 650 13. Simpson, D.S., et al., *Interferon- γ primes macrophages for pathogen ligand-induced*
651 *killing via a caspase-8 and mitochondrial cell death pathway*. *Immunity*, 2022. **55**(3): p. 423-
652 441.e9.
- 653 14. Ramakrishnan, M.A., *Determination of 50% endpoint titer using a simple formula*. *World J*
654 *Virol*, 2016. **5**(2): p. 85-6.
- 655 15. Emily, M.E., et al., *Cohort Profile: A longitudinal Victorian COVID-19 cohort (COVID*
656 *PROFILE)*. medRxiv, 2023: p. 2023.04.27.23289157.
- 657 16. Harris, P.A., et al., *Research electronic data capture (REDCap)--a metadata-driven*
658 *methodology and workflow process for providing translational research informatics support*.
659 *J Biomed Inform*, 2009. **42**(2): p. 377-81.
- 660 17. Harris, P.A., et al., *The REDCap consortium: Building an international community of*
661 *software platform partners*. *J Biomed Inform*, 2019. **95**: p. 103208.
- 662 18. Huang, X. and Y. Huang, *Cellsnp-lite: an efficient tool for genotyping single cells*.
663 *Bioinformatics*, 2021. **37**(23): p. 4569-4571.
- 664 19. Huang, Y., D.J. McCarthy, and O. Stegle, *Vireo: Bayesian demultiplexing of pooled single-*
665 *cell RNA-seq data without genotype reference*. *Genome Biology*, 2019. **20**(1): p. 273.
- 666 20. Hafemeister, C. and R. Satija, *Normalization and variance stabilization of single-cell RNA-*
667 *seq data using regularized negative binomial regression*. *Genome Biol*, 2019. **20**(1): p. 296.
- 668 21. Stuart, T., et al., *Comprehensive Integration of Single-Cell Data*. *Cell*, 2019. **177**(7): p. 1888-
669 1902.e21.
- 670 22. Aran, D., et al., *Reference-based analysis of lung single-cell sequencing reveals a transitional*
671 *profibrotic macrophage*. *Nature Immunology*, 2019. **20**(2): p. 163-172.
- 672 23. Wu, T., et al., *clusterProfiler 4.0: A universal enrichment tool for interpreting omics data*.
673 *The Innovation*, 2021. **2**(3).
- 674 24. Love, M.I., W. Huber, and S. Anders, *Moderated estimation of fold change and dispersion for*
675 *RNA-seq data with DESeq2*. *Genome Biology*, 2014. **15**(12): p. 550.
- 676 25. Zyla, J., et al., *Gene set enrichment for reproducible science: comparison of CERNO and*
677 *eight other algorithms*. *Bioinformatics*, 2019. **35**(24): p. 5146-5154.
- 678 26. Cai, Y., et al., *Single-cell transcriptomics of blood reveals a natural killer cell subset*
679 *depletion in tuberculosis*. *EBioMedicine*, 2020. **53**.
- 680 27. Berry, M.P.R., et al., *An interferon-inducible neutrophil-driven blood transcriptional*
681 *signature in human tuberculosis*. *Nature*, 2010. **466**(7309): p. 973-977.

- 682 28. Bloom, C.I., et al., *Transcriptional blood signatures distinguish pulmonary tuberculosis,*
683 *pulmonary sarcoidosis, pneumonias and lung cancers.* PLoS One, 2013. **8**(8): p. e70630.
- 684 29. Scriba, T.J., et al., *Sequential inflammatory processes define human progression from M.*
685 *tuberculosis infection to tuberculosis disease.* PLoS Pathog, 2017. **13**(11): p. e1006687.
- 686 30. Schulte-Schrepping, J., et al., *Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell*
687 *Compartment.* Cell, 2020. **182**(6): p. 1419-1440.e23.
- 688 31. Silvin, A., et al., *Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate*
689 *Severe from Mild COVID-19.* Cell, 2020. **182**(6): p. 1401-1418.e18.
- 690 32. Cooper, A.M., et al., *Disseminated tuberculosis in interferon gamma gene-disrupted mice.* J
691 Exp Med, 1993. **178**(6): p. 2243-7.
- 692 33. Flynn, J.L., et al., *An essential role for interferon gamma in resistance to Mycobacterium*
693 *tuberculosis infection.* J Exp Med, 1993. **178**(6): p. 2249-54.
- 694 34. Flynn, J.L., et al., *Tumor necrosis factor-alpha is required in the protective immune response*
695 *against Mycobacterium tuberculosis in mice.* Immunity, 1995. **2**(6): p. 561-72.
- 696 35. Karki, R., et al., *Synergism of TNF- α and IFN- γ ; Triggers Inflammatory Cell*
697 *Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock*
698 *Syndromes.* Cell, 2021. **184**(1): p. 149-168.e17.
- 699 36. Li, S., et al., *SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8*
700 *activation.* Signal Transduction and Targeted Therapy, 2020. **5**(1): p. 235.
- 701 37. André, S., et al., *T cell apoptosis characterizes severe Covid-19 disease.* Cell Death &
702 Differentiation, 2022. **29**(8): p. 1486-1499.
- 703 38. Zhang, D., et al., *Frontline Science: COVID-19 infection induces readily detectable*
704 *morphologic and inflammation-related phenotypic changes in peripheral blood monocytes.* J
705 Leukoc Biol, 2021. **109**(1): p. 13-22.
- 706 39. Lastrucci, C., et al., *Tuberculosis is associated with expansion of a motile, permissive and*
707 *immunomodulatory CD16+ monocyte population via the IL-10/STAT3 axis.* Cell Research,
708 2015. **25**(12): p. 1333-1351.
- 709 40. Hadjadj, J., et al., *Impaired type I interferon activity and inflammatory responses in severe*
710 *COVID-19 patients.* Science, 2020. **369**(6504): p. 718.
- 711 41. Arunachalam, P.S., et al., *Systems biological assessment of immunity to mild versus severe*
712 *COVID-19 infection in humans.* Science, 2020. **369**(6508): p. 1210-1220.
- 713 42. Israelow, B., et al., *Mouse model of SARS-CoV-2 reveals inflammatory role of type I*
714 *interferon signaling.* J Exp Med, 2020. **217**(12).
- 715 43. Zak, D.E., et al., *A blood RNA signature for tuberculosis disease risk: a prospective cohort*
716 *study.* Lancet, 2016. **387**(10035): p. 2312-2322.
- 717 44. Singhanian, A., et al., *A modular transcriptional signature identifies phenotypic heterogeneity*
718 *of human tuberculosis infection.* Nat Commun, 2018. **9**(1): p. 2308.
- 719 45. Esmail, H., et al., *Complement pathway gene activation and rising circulating immune*
720 *complexes characterize early disease in HIV-associated tuberculosis.* Proceedings of the
721 National Academy of Sciences, 2018. **115**(5): p. E964-E973.

- 722 46. Zhang, G., et al., *A proline deletion in IFNAR1 impairs IFN-signaling and underlies*
723 *increased resistance to tuberculosis in humans*. Nature Communications, 2018. **9**(1): p. 85.
- 724 47. Desvignes, L., A.J. Wolf, and J.D. Ernst, *Dynamic roles of type I and type II IFNs in early*
725 *infection with Mycobacterium tuberculosis*. J Immunol, 2012. **188**(12): p. 6205-15.
- 726 48. Mesev, E.V., R.A. LeDesma, and A. Ploss, *Decoding type I and III interferon signalling*
727 *during viral infection*. Nat Microbiol, 2019. **4**(6): p. 914-924.
- 728 49. Liu, J., et al., *Longitudinal characteristics of lymphocyte responses and cytokine profiles in*
729 *the peripheral blood of SARS-CoV-2 infected patients*. eBioMedicine, 2020. **55**.
- 730 50. Wilk, A.J., et al., *A single-cell atlas of the peripheral immune response in patients with severe*
731 *COVID-19*. Nature Medicine, 2020. **26**(7): p. 1070-1076.
- 732 51. Pires, D., et al., *Role of Cathepsins in Mycobacterium tuberculosis Survival in Human*
733 *Macrophages*. Sci Rep, 2016. **6**: p. 32247.
- 734 52. Zhang, Q., et al., *Molecular mechanism of interaction between SARS-CoV-2 and host cells*
735 *and interventional therapy*. Signal Transduction and Targeted Therapy, 2021. **6**(1): p. 233.
- 736 53. Mathew, D., et al., *Deep immune profiling of COVID-19 patients reveals distinct*
737 *immunotypes with therapeutic implications*. Science, 2020. **369**(6508).
- 738 54. Kuri-Cervantes, L., et al., *Comprehensive mapping of immune perturbations associated with*
739 *severe COVID-19*. Sci Immunol, 2020. **5**(49).
- 740 55. Ardain, A., et al., *Group 3 innate lymphoid cells mediate early protective immunity against*
741 *tuberculosis*. Nature, 2019. **570**(7762): p. 528-532.
- 742 56. Roy Chowdhury, R., et al., *A multi-cohort study of the immune factors associated with M.*
743 *tuberculosis infection outcomes*. Nature, 2018. **560**(7720): p. 644-648.
- 744 57. Allen, M., et al., *Mechanisms of Control of Mycobacterium tuberculosis by NK Cells: Role of*
745 *Glutathione*. Front Immunol, 2015. **6**: p. 508.
- 746 58. Sefik, E., et al., *Inflammasome activation in infected macrophages drives COVID-19*
747 *pathology*. Nature, 2022. **606**(7914): p. 585-593.
- 748 59. Chang, J.J., et al., *Long-Read RNA Sequencing Identifies Polyadenylation Elongation and*
749 *Differential Transcript Usage of Host Transcripts During SARS-CoV-2 In Vitro Infection*.
750 Front Immunol, 2022. **13**: p. 832223.

751

752 **Data Availability Statement**

753 The raw fastq files and processed transcript count matrices for this study can be found in the gene
754 expression omnibus database under the accession number GSE232705. The scripts used to analyse
755 these data have been uploaded to GitHub - [https://github.com/sheerind-wehi/Mtb_SARS_co-](https://github.com/sheerind-wehi/Mtb_SARS_co-infection)
756 [infection](https://github.com/sheerind-wehi/Mtb_SARS_co-infection)

757

